Small molecule · Inhibitor of phosphoinositide 3-kinase delta (PIK3CD) and casein kinase 1 epsilon (CSNK1E) · developed by Tg Theraps
Umbralisib is an orally available kinase inhibitor that targets the delta isoform of PI3K and casein kinase 1 epsilon, suppressing PI3K/AKT signaling and reducing proliferation and migration of B-cell lymphoma cells.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Dec 15, 2022). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03801525 | Phase 2/3 | Chronic Lymphocytic Leukemia | Terminated | TGTX |
| NCT02612311 | Phase 3 | Chronic Lymphocytic Leukemia | Terminated | TGTX |
| NCT03207256 | Phase 2 | Chronic Lymphocytic Leukemia | Terminated | TGTX |
| NCT02164006 | Phase 1 | Hodgkin's Lymphoma | Completed | TGTX |
| NCT02100852 | Phase 1 | Chronic Lymphocytic Leukemia | Completed | TGTX |
| NCT02006485 | Phase 1 | Chronic Lymphocytic Leukemia | Completed | TGTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Lymphocytic LeukemiaNon Hodgkin LymphomaNon-Hodgkin's LymphomaSmall Lymphocytic Lymphoma
Updated Nov 1, 2026.